![]() ![]() “We generated record results in the third quarter and made significant progress executing our R&D strategy, further expanding our pipeline with five new programs,” said Tim Walbert, chairman, president and chief executive officer, Horizon. 3, 2021- Horizon Therapeutics plc (Nasdaq: HZNP) today announced record third-quarter 2021 financial results and increased both its full-year 2021 net sales and adjusted EBITDA guidance. 30, 2021, Ahead of Year-End 2021 Goal -ĭUBLIN-(BUSINESS WIRE)-Nov. ![]() ![]() Cash Position of $1.07 Billion Achieved Gross Leverage Target of 2.0 Times at Sept. Initiated Enrollment in TEPEZZA Chronic Thyroid Eye Disease (TED) Trial Results Expected in Second Half of 2022. Announced Positive Topline Data from MIRROR Trial Evaluating the Use of KRYSTEXXA Plus Methotrexate 71 Percent of Patients Achieved a Complete Response Rate at Month 6 Expect to Submit a Supplemental Biologics License Application (sBLA) to the U.S. Announced Five New Programs for Development-Stage Candidates Daxdilimab (HZN-7734) and Dazodalibep (HZN-4920). Increasing Full-Year 2021 Net Sales Guidance to $3.16 Billion to $3.21 Billion, Representing 45 Percent Growth at the Midpoint Increasing Full-Year 2021 Adjusted EBITDA Guidance to $1.315 Billion to $1.345 Billion, Representing 33 Percent Growth at the Midpoint. ![]() Record KRYSTEXXA® (pegloticase injection) Third-Quarter 2021 Net Sales of $158.1 Million KRYSTEXXA Plus Immunomodulation Now at More Than 45 Percent Increasing Full-Year 2021 Net Sales Guidance to Greater Than $550 Million, Representing Year-Over-Year Growth of More Than 35 Percent. Record TEPEZZA ® (teprotumumab-trbw) Third-Quarter 2021 Net Sales of $616.4 Million Increasing Full-Year 2021 Net Sales Guidance to Greater Than $1.625 Billion, Representing Year-Over-Year Growth of More Than 98 Percent. But he said the firm dropped its overweight positioning on consumer staples, wile also changing its underweight rating on the materials sector.- Record Third-Quarter 2021 Net Sales of $1.037 Billion Increased 63 Percent Third-Quarter 2021 GAAP Net Income of $326.5 Million Record Adjusted EBITDA of $509.0 Million. Willer said he still favors technology, energy and industrial stocks over utilities, financials and real estate. "But with the AI story continuing, we would be buyer on dips." "Equities have climbed the proverbial 'Wall of Worry' and are now somewhat overbought," Willer said. That's especially true considering excitement artificial intelligence continues to build within the market, he added. He said investors should be prepared to be patient, but also watch for any moves down as they still could make for good times to buy in. But investors should now be wondering if stocks as a whole have been overbought.Įquities are "somewhat overstretched" as the market enters a period of negative seasonality, he warned in a note to clients. There's little left to worry about in the market in terms of impacts from an economic shift, according to Citi analyst Dirk Willer. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower Best Debt Consolidation Loans for Bad Credit ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |